Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8008338 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2027
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8207215 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(24 days from now) | |
US9216167 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(24 days from now) | |
US8648107 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(24 days from now) | |
US8541463 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(24 days from now) | |
US8906950 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(24 days from now) | |
US9216127 | ABBVIE | Burial vault and method for customizing a burial vault |
May, 2024
(24 days from now) | |
US8377982 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(24 days from now) | |
US8946281 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(24 days from now) | |
US8377982 (Pediatric) | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(6 months from now) | |
US8207215 (Pediatric) | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(6 months from now) | |
US8541463 (Pediatric) | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(6 months from now) | |
US8008338 (Pediatric) | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2027
(3 years from now) |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 30 May, 2003
Treatment: A method of controlling postoperative ocular pain and burning/stinging in a patient; A method of treating ocular pain and/or enhancing ocular comfort; A method of treating or reducing ocular pain and ...
Dosage: SOLUTION/DROPS;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7842714 | ABBVIE | Ketorolac tromethamine compositions for treating ocular pain |
Aug, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8992952 | ABBVIE | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
Aug, 2024
(3 months from now) | |
US8512717 | ABBVIE | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
Mar, 2028
(3 years from now) | |
US9192571 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Mar, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jul 22, 2012 |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 22 July, 2009
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6620435 | ABBVIE | Compositions for topical application of therapeutic agents |
Sep, 2016
(7 years ago) | |
US5863560 | ABBVIE | Compositions and methods for topical application of therapeutic agents |
Sep, 2016
(7 years ago) | |
US6060085 | ABBVIE | Compositions and methods for topical application of therapeutic agents |
Sep, 2016
(7 years ago) |
Drugs and Companies using DAPSONE ingredient
Market Authorisation Date: 07 July, 2005
Treatment: Treatment of acne
Dosage: GEL;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6406715 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles |
Sep, 2013
(10 years ago) | |
US6676967 | ABBVIE | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
Sep, 2013
(10 years ago) | |
US6129930 | ABBVIE | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
Sep, 2013
(10 years ago) | |
US7011848 | ABBVIE | Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep, 2013
(10 years ago) | |
US7998506 | ABBVIE | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep, 2013
(10 years ago) | |
US6818229 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
Sep, 2013
(10 years ago) | |
US6746691 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
Sep, 2013
(10 years ago) | |
US6080428 | ABBVIE | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
May, 2017
(6 years ago) | |
US6469035 | ABBVIE | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
Mar, 2018
(6 years ago) |
Drugs and Companies using LOVASTATIN; NIACIN ingredient
Market Authorisation Date: 17 December, 2001
Treatment: Intermediate rel nicotinic acid formulations having unique urinary metab profiles resulting from absorption profiles of nicotinic acid from the intermediate nicotinic acid formulations,suitable for tx...
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5424078 (Pediatric) | ABBVIE | Aqueous ophthalmic formulations and methods for preserving same |
Dec, 2012
(11 years ago) | |
US10307368 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
US9295641 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
US9687443 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
US6562873 | ABBVIE | Compositions containing therapeutically active components having enhanced solubility |
Jul, 2021
(2 years ago) | |
US6627210 | ABBVIE | Compositions containing α-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
US6673337 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
US6641834 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
US9295641 (Pediatric) | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(2 years ago) | |
US6562873 (Pediatric) | ABBVIE | Compositions containing therapeutically active components having enhanced solubility |
Jan, 2022
(2 years ago) | |
US9687443 (Pediatric) | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(2 years ago) | |
US6627210 (Pediatric) | ABBVIE | Compositions containing α-2-adrenergic agonist components |
Jan, 2022
(2 years ago) | |
US6673337 (Pediatric) | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(2 years ago) | |
US6641834 (Pediatric) | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(2 years ago) | |
US8858961 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Sep, 2023
(8 months ago) | |
US8858961 (Pediatric) | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Mar, 2024
(2 months ago) |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 16 March, 2001
Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension
Dosage: SOLUTION/DROPS;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5541170 | ABBVIE | Orally administrable pharmaceutical compositions |
Jul, 2013
(10 years ago) | |
US5541171 | ABBVIE | Orally administrable pharmaceutical composition |
Jul, 2013
(10 years ago) | |
US6893662 | ABBVIE | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
Nov, 2021
(2 years ago) | |
US8580302 | ABBVIE | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
Nov, 2021
(2 years ago) | |
US9089492 | ABBVIE | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
Nov, 2021
(2 years ago) |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 29 May, 2008
Treatment: Treatment of ulcerative colitis
Dosage: TABLET, DELAYED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6010718 | ABBVIE | Extended release formulations of erythromycin derivatives |
Apr, 2017
(7 years ago) | |
US6551616 | ABBVIE | Extended release formulations of erythromycin derivatives |
Jul, 2017
(6 years ago) |
Drugs and Companies using CLARITHROMYCIN ingredient
Market Authorisation Date: 03 March, 2000
Treatment: Treatment of mild to moderate infection caused by susceptible strains
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7803838 | ABBVIE | Compositions comprising nebivolol |
Aug, 2026
(2 years from now) | |
US7838552 | ABBVIE | Compositions comprising nebivolol |
Oct, 2027
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Jun 03, 2019 |
Drugs and Companies using NEBIVOLOL HYDROCHLORIDE; VALSARTAN ingredient
Market Authorisation Date: 03 June, 2016
Treatment: Method of treating hypertension
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6051567 | ABBVIE | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
Aug, 2019
(4 years ago) | |
US6274169 | ABBVIE | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
Aug, 2019
(4 years ago) | |
US6265392 | ABBVIE | Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol |
Aug, 2019
(4 years ago) | |
US6274169 (Pediatric) | ABBVIE | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
Feb, 2020
(4 years ago) | |
US6265392 (Pediatric) | ABBVIE | Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol |
Feb, 2020
(4 years ago) | |
US6051567 (Pediatric) | ABBVIE | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
Feb, 2020
(4 years ago) |
Drugs and Companies using CALCITRIOL ingredient
Market Authorisation Date: 25 September, 1986
Treatment: NA
Dosage: INJECTABLE;INJECTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8436051 | ABBVIE | Mesalamine suppository |
Jun, 2028
(4 years from now) | |
US8217083 | ABBVIE | Mesalamine suppository |
Jun, 2028
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-187) | Sep 02, 2019 |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 05 November, 2004
Treatment: NA
Dosage: SUPPOSITORY;RECTAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7030149 | ABBVIE | Combination of brimonidine timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
US7642258 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
US9907801 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
US8133890 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
US8748425 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
US9770453 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
US7320976 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
US9907802 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
US8354409 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
US9474751 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
US7323463 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Jan, 2023
(1 year, 3 months ago) |
Drugs and Companies using BRIMONIDINE TARTRATE; TIMOLOL MALEATE ingredient
Market Authorisation Date: 30 October, 2007
Treatment: Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop. dose is one drop of ...
Dosage: SOLUTION/DROPS;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9198871 | ABBVIE | Delayed release pancreatin compositions |
Feb, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 30, 2014 |
M(M-93) | Jul 29, 2019 |
New Indication(I-625) | Apr 30, 2013 |
Drugs and Companies using PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) ingredient
NCE-1 date: 30 April, 2013
Market Authorisation Date: 30 April, 2009
Treatment: Treatment of exocrine pancreatic insufficiency
Dosage: CAPSULE, DELAYED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7119061 | ABBVIE | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(5 months ago) | |
US7115564 | ABBVIE | Stable pharmaceutical compositions of dalbavancin and methods of administration |
Nov, 2023
(5 months ago) | |
US8143212 | ABBVIE | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(5 months ago) | |
US6900175 | ABBVIE | Methods of administering dalbavancin for treatment of bacterial infections |
May, 2028
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 23, 2019 |
New Patient Population(NPP) | Jul 22, 2024 |
Generating Antibiotic Incentives Now(GAIN) | May 23, 2024 |
New Dosing Schedule(D-154) | Jan 20, 2019 |
Drugs and Companies using DALBAVANCIN HYDROCHLORIDE ingredient
NCE-1 date: 24 May, 2023
Market Authorisation Date: 23 May, 2014
Treatment: Treatment of bacterial infections using a two-dose regimen of dalbavancin.; Treatment of acute bacterial skin and skin structure infections (absssi) in adult and pediatric patients using a two-dose re...
Dosage: POWDER;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5541170 | ABBVIE | Orally administrable pharmaceutical compositions |
Jul, 2013
(10 years ago) | |
US5541171 | ABBVIE | Orally administrable pharmaceutical composition |
Jul, 2013
(10 years ago) | |
US6649180 | ABBVIE | Hard capsule formed of cellulose ether film with a specific content of methoxyl and hydroxypropoxyl groups |
Apr, 2020
(4 years ago) |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 01 February, 2013
Treatment: Treatment of ulcerative colitis
Dosage: CAPSULE, DELAYED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6720004 | ABBVIE | Controlled release formulation of divalproex sodium |
Dec, 2018
(5 years ago) | |
US6713086 | ABBVIE | Controlled release formulation of divalproex sodium |
Dec, 2018
(5 years ago) | |
US6528090 | ABBVIE | Controlled release formulation of divalproex sodium |
Dec, 2018
(5 years ago) | |
US6419953 | ABBVIE | Controlled release formulation of divalproex sodium |
Dec, 2018
(5 years ago) | |
US6528091 | ABBVIE | Controlled release formulation of divalproex sodium |
Dec, 2018
(5 years ago) | |
US6511678 | ABBVIE | Controlled release formulation of divalproex sodium |
Dec, 2018
(5 years ago) | |
US6511678 (Pediatric) | ABBVIE | Controlled release formulation of divalproex sodium |
Jun, 2019
(4 years ago) | |
US6528090 (Pediatric) | ABBVIE | Controlled release formulation of divalproex sodium |
Jun, 2019
(4 years ago) | |
US6713086 (Pediatric) | ABBVIE | Controlled release formulation of divalproex sodium |
Jun, 2019
(4 years ago) | |
US6419953 (Pediatric) | ABBVIE | Controlled release formulation of divalproex sodium |
Jun, 2019
(4 years ago) | |
US6528091 (Pediatric) | ABBVIE | Controlled release formulation of divalproex sodium |
Jun, 2019
(4 years ago) | |
US6720004 (Pediatric) | ABBVIE | Controlled release formulation of divalproex sodium |
Jun, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Pediatric Exclusivity(PED) | Sep 24, 2011 |
Drugs and Companies using DIVALPROEX SODIUM ingredient
Market Authorisation Date: 31 May, 2002
Treatment: Treatment of epilepsy and/or migraine.; Treatment of epilepsy
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8629185 | ABBVIE | 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof |
Jul, 2031
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7033605 | ABBVIE | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
Oct, 2020
(3 years ago) | |
US10398707 | ABBVIE | Hypotensive lipid-containing biodegradable intraocular implants and related implants |
Apr, 2024
(3 days ago) | |
US8673341 | ABBVIE | Intraocular pressure reduction with intracameral bimatoprost implants |
Feb, 2025
(9 months from now) | |
US9149428 | ABBVIE | Processes for making cyclic lipid implants for intraocular use |
Dec, 2026
(2 years from now) | |
US10441543 | ABBVIE | Processes for making cyclic lipid implants for intraocular use |
Dec, 2026
(2 years from now) | |
US8206737 | ABBVIE | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
Apr, 2027
(2 years from now) | |
US7799336 | ABBVIE | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
Apr, 2029
(4 years from now) | |
US9492316 | ABBVIE | Prostamide-containing intraocular implants and methods of use thereof |
Oct, 2034
(10 years from now) | |
US9980974 | ABBVIE | Prostamide-containing intraocular implants and methods of use thereof |
Oct, 2034
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Mar 04, 2023 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 04 March, 2020
Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant
Dosage: IMPLANT;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5096890 | ABBVIE | Pyrrolidine derivatives |
Mar, 2015
(9 years ago) | |
US6106864 | ABBVIE | Pharmaceutical formulations containing darifenacin |
Aug, 2016
(7 years ago) |
Drugs and Companies using DARIFENACIN HYDROBROMIDE ingredient
Market Authorisation Date: 22 December, 2004
Treatment: Treating a disease of altered motility or tone of smooth muscle by administering a muscarinic receptor antagonizing amount of darifenacin; Treating urinary incontinence by administering an extended-re...
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8865937 | ABBVIE | Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide |
May, 2032
(8 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE43879 | ABBVIE | Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug |
Jan, 2026
(1 year, 8 months from now) | |
US8481598 | ABBVIE | Stable dosage forms of levomilnacipran |
Mar, 2031
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
NCE*(NCE*) | Jul 25, 2018 |
M(M-249) | Oct 07, 2022 |
Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient
Market Authorisation Date: 25 July, 2013
Treatment: Treatment of major depressive disorder (mdd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7029694 | ABBVIE | Compositions and methods for transdermal oxybutynin therapy |
Apr, 2020
(4 years ago) | |
US8241662 | ABBVIE | Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy |
Apr, 2020
(4 years ago) | |
US7179483 | ABBVIE | Compositions and methods for transdermal oxybutynin therapy |
Apr, 2020
(4 years ago) | |
US10272061 | ABBVIE | Compositions and methods for unoccluded transdermal oxybutynin therapy |
Apr, 2020
(4 years ago) | |
US9259388 | ABBVIE | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Nov, 2029
(5 years from now) | |
US10449173 | ABBVIE | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Nov, 2029
(5 years from now) | |
US8920392 | ABBVIE | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Mar, 2031
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | Jan 27, 2012 |
Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient
Market Authorisation Date: 27 January, 2009
Treatment: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence; Treatment of patients with an overactive bladder with symptoms of urinary frequency,...
Dosage: GEL;TRANSDERMAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5541206 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2013
(10 years ago) | |
US5948436 | ABBVIE | Pharmaceutical composition |
Sep, 2013
(10 years ago) | |
US5886036 | ABBVIE | Retroviral protease inhibiting compounds |
Nov, 2013
(10 years ago) | |
US5484801 | ABBVIE | Pharmaceutical composition for inhibiting HIV protease |
Jan, 2014
(10 years ago) | |
US5541206 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2014
(10 years ago) | |
US5948436 (Pediatric) | ABBVIE | Pharmaceutical composition |
Mar, 2014
(10 years ago) | |
US5886036 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
May, 2014
(9 years ago) | |
US5648497 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2014
(9 years ago) | |
US5484801 (Pediatric) | ABBVIE | Pharmaceutical composition for inhibiting HIV protease |
Jul, 2014
(9 years ago) | |
US5648497 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2015
(9 years ago) | |
US5914332 | ABBVIE | Retroviral protease inhibiting compounds |
Dec, 2015
(8 years ago) | |
US6284767 | ABBVIE | Retroviral protease inhibiting compounds |
Feb, 2016
(8 years ago) | |
US5914332 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jun, 2016
(7 years ago) | |
US6703403 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
US6037157 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
US6284767 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Aug, 2016
(7 years ago) | |
US6703403 (Pediatric) | ABBVIE | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
US6037157 (Pediatric) | ABBVIE | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
US6458818 | ABBVIE | Pharmaceutical composition |
Nov, 2017
(6 years ago) | |
US6521651 | ABBVIE | Pharmaceutical composition |
Nov, 2017
(6 years ago) | |
US6232333 | ABBVIE | Pharmaceutical composition |
Nov, 2017
(6 years ago) | |
US6521651 (Pediatric) | ABBVIE | Pharmaceutical composition |
May, 2018
(5 years ago) | |
US6458818 (Pediatric) | ABBVIE | Pharmaceutical composition |
May, 2018
(5 years ago) | |
US6232333 (Pediatric) | ABBVIE | Pharmaceutical composition |
May, 2018
(5 years ago) | |
US7148359 | ABBVIE | Polymorph of a pharmaceutical |
Jul, 2019
(4 years ago) | |
US7148359 (Pediatric) | ABBVIE | Polymorph of a pharmaceutical |
Jan, 2020
(4 years ago) | |
US7141593 | ABBVIE | Pharmaceutical formulations |
May, 2020
(3 years ago) | |
US7432294 | ABBVIE | Pharmaceutical formulations |
May, 2020
(3 years ago) | |
US7364752 | ABBVIE | Solid dispersion pharamaceutical formulations |
Nov, 2020
(3 years ago) | |
US7432294 (Pediatric) | ABBVIE | Pharmaceutical formulations |
Nov, 2020
(3 years ago) | |
US7141593 (Pediatric) | ABBVIE | Pharmaceutical formulations |
Nov, 2020
(3 years ago) | |
US7364752 (Pediatric) | ABBVIE | Solid dispersion pharamaceutical formulations |
May, 2021
(2 years ago) | |
US8501219 | ABBVIE | Flavoring systems for pharmaceutical compositions and methods of making such compositions |
Nov, 2021
(2 years ago) | |
US6911214 | ABBVIE | Flavoring systems for pharmaceutical compositions and methods of making such compositions |
Nov, 2021
(2 years ago) | |
US6911214 (Pediatric) | ABBVIE | Flavoring systems for pharmaceutical compositions and methods of making such compositions |
May, 2022
(1 year, 11 months ago) | |
US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
US8691878 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
US8309613 | ABBVIE | Solid pharmaceutical dosage form |
Dec, 2024
(7 months from now) | |
US8691878 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
US8399015 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
US8268349 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
US8309613 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Jun, 2025
(1 year, 1 month from now) | |
US8470347 | ABBVIE | Self-emulsifying active substance formulation and use of this formulation |
Sep, 2026
(2 years from now) | |
US8470347 (Pediatric) | ABBVIE | Self-emulsifying active substance formulation and use of this formulation |
Mar, 2027
(2 years from now) | |
US8377952 | ABBVIE | Solid pharmaceutical dosage formulation |
Oct, 2027
(3 years from now) | |
US8025899 | ABBVIE | Solid pharmaceutical dosage form |
Dec, 2027
(3 years from now) | |
US8377952 (Pediatric) | ABBVIE | Solid pharmaceutical dosage formulation |
Apr, 2028
(3 years from now) | |
US8025899 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Jun, 2028
(4 years from now) |
Drugs and Companies using LOPINAVIR; RITONAVIR ingredient
Market Authorisation Date: 15 September, 2000
Treatment: Treatment of hiv-infection in combination with other antiretroviral agents; Treatment of hiv infection in combination with other antiretroviral agents; Treatment of hiv infection; Treatment of hiv-1 i...
Dosage: CAPSULE;ORAL; TABLET;ORAL; SOLUTION;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8242294 | ABBVIE | Synthetic bile acid compositions and methods |
May, 2028
(4 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8846066 | ABBVIE | Methods and related compositions for reduction of fat and skin tightening |
Feb, 2025
(9 months from now) | |
US8298556 | ABBVIE | Methods and related compositions for the non-surgical removal of fat |
Aug, 2025
(1 year, 2 months from now) | |
US7622130 | ABBVIE | Methods and compositions for the non-surgical removal of fat |
Dec, 2027
(3 years from now) | |
US7754230 | ABBVIE | Methods and related compositions for reduction of fat |
Dec, 2027
(3 years from now) | |
US8461140 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(3 years from now) | |
US8883770 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(3 years from now) | |
US9522155 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(3 years from now) | |
US9636349 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(3 years from now) | |
US9949986 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(3 years from now) | |
US8546367 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(3 years from now) | |
US8653058 | ABBVIE | Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits |
Mar, 2030
(5 years from now) | |
US8101593 | ABBVIE | Formulations of deoxycholic acid and salts thereof |
Mar, 2030
(5 years from now) | |
US8367649 | ABBVIE | Formulations of deoxycholic acid and salts thereof |
Mar, 2030
(5 years from now) | |
US10500214 | ABBVIE | Formulations of deoxycholic acid and salts thereof |
Mar, 2030
(5 years from now) |
Drugs and Companies using DEOXYCHOLIC ACID ingredient
Market Authorisation Date: 29 April, 2015
Treatment: Method for reduction of submental fat; Improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults by means of reducing submental fat volume as de...
Dosage: SOLUTION;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5468743 | ABBVIE | Imidazo[2,1-b]benzazepine derivatives, compositions and method of use |
Nov, 2013
(10 years ago) | |
US10617695 | ABBVIE | Ophthalmic compositions containing alcaftadine |
Mar, 2027
(2 years from now) | |
US8664215 | ABBVIE | Ocular allergy treatments with alcaftadine |
Dec, 2027
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 28, 2015 |
Drugs and Companies using ALCAFTADINE ingredient
NCE-1 date: 28 July, 2014
Market Authorisation Date: 28 July, 2010
Treatment: Use of lastacaft to temporary relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
Dosage: SOLUTION/DROPS;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6403649 | ABBVIE | Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Sep, 2012
(11 years ago) | |
US8017655 | ABBVIE | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Nov, 2012
(11 years ago) | |
US8541466 | ABBVIE | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan, 2021
(3 years ago) | |
US8906962 | ABBVIE | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan, 2021
(3 years ago) | |
US9579270 | ABBVIE | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan, 2021
(3 years ago) | |
US7388029 | ABBVIE | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan, 2022
(2 years ago) | |
US8986715 | ABBVIE | Method of enhancing hair growth |
Jan, 2023
(1 year, 3 months ago) | |
US9216183 | ABBVIE | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(1 year, 3 months ago) | |
US9226931 | ABBVIE | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(1 year, 3 months ago) | |
US8758733 | ABBVIE | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(1 year, 3 months ago) | |
US8926953 | ABBVIE | Method of enhancing hair growth |
Jan, 2023
(1 year, 3 months ago) | |
US8632760 | ABBVIE | Method of enhancing hair growth |
Jan, 2023
(1 year, 3 months ago) | |
US8038988 | ABBVIE | Method of enhancing hair growth |
Aug, 2023
(8 months ago) | |
US8263054 | ABBVIE | Method of enhancing hair growth |
Aug, 2023
(8 months ago) | |
US8101161 | ABBVIE | Method of enhancing hair growth |
May, 2024
(21 days from now) | |
US7351404 | ABBVIE | Method of enhancing hair growth |
May, 2024
(21 days from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Dec 24, 2011 |
M(M-140) | Sep 04, 2017 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 24 December, 2008
Treatment: Method of increasing hair growth; Method of increasing eyelash growth with bimatoprost; Treatment of hair loss and hypotrichosis of the eyelashes by increasing their growth including length, thickness...
Dosage: SOLUTION/DROPS;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7420069 | ABBVIE | Crystalline composition containing escitalopram |
Aug, 2022
(1 year, 8 months ago) | |
US6916941 | ABBVIE | Crystalline composition containing escitalopram |
Aug, 2022
(1 year, 8 months ago) | |
US6916941 (Pediatric) | ABBVIE | Crystalline composition containing escitalopram |
Feb, 2023
(1 year, 2 months ago) | |
US7420069 (Pediatric) | ABBVIE | Crystalline composition containing escitalopram |
Feb, 2023
(1 year, 2 months ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | May 12, 2026 |
Drugs and Companies using ESCITALOPRAM OXALATE ingredient
Market Authorisation Date: 14 August, 2002
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7745409 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(3 months ago) | |
US7371727 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(3 months ago) | |
US7704947 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(3 months ago) | |
US8080526 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(3 months ago) | |
US7304036 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Aug, 2026
(2 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8110553 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(3 months ago) | |
US8933030 | ABBVIE | Treatments for gastrointestinal disorders |
Feb, 2031
(6 years from now) | |
US10702576 | ABBVIE | Stable formulations of linaclotide |
Aug, 2031
(7 years from now) | |
US10675325 | ABBVIE | Stable formulations of linaclotide |
Aug, 2031
(7 years from now) | |
US8748573 | ABBVIE | Formulations comprising linaclotide |
Oct, 2031
(7 years from now) | |
US8802628 | ABBVIE | Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration |
Oct, 2031
(7 years from now) | |
US9708371 | ABBVIE | Treatments for gastrointestinal disorders |
Aug, 2033
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-921) | Jun 12, 2026 |
New Strength(NS) | Jan 25, 2020 |
New Chemical Entity Exclusivity(NCE) | Aug 30, 2017 |
Drugs and Companies using LINACLOTIDE ingredient
NCE-1 date: 30 August, 2016
Market Authorisation Date: 30 August, 2012
Treatment: Method of treating irritable bowel syndrome with constipation in adults; Treatment of functional constipation in pediatric patients 6 to 17 years of age; Method of treating irritable bowel syndrome wi...
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7851504 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Jun, 2027
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6403649 | ABBVIE | Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Sep, 2012
(11 years ago) | |
US8017655 | ABBVIE | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Nov, 2012
(11 years ago) | |
US5688819 | ABBVIE | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Aug, 2014
(9 years ago) | |
US9241918 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
US8586630 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
US8524777 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
US8309605 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
US8299118 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
US8772338 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
US8933120 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
US8933127 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
US8278353 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
US9155716 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
US8338479 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 16 March, 2001
Treatment: Lumigan is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Topical treatment of ocular hypertension and...
Dosage: SOLUTION/DROPS;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5744496 | ABBVIE | Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors |
Apr, 2015
(9 years ago) |
Drugs and Companies using TRANDOLAPRIL ingredient
Market Authorisation Date: 26 April, 1996
Treatment: Cardiac insufficiency (congestive heart failure)
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8648037 | ABBVIE | Macrocyclic proline derived HCV serine protease inhibitors |
Jan, 2032
(7 years from now) | |
US8937150 | ABBVIE | Anti-viral compounds |
May, 2032
(8 years from now) | |
USRE48923 | ABBVIE | Crystal forms |
May, 2035
(11 years from now) | |
US9321807 | ABBVIE | Crystal forms |
Jun, 2035
(11 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10039754 | ABBVIE | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
US10028937 | ABBVIE | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
US9586978 | ABBVIE | Anti-viral compounds |
Nov, 2030
(6 years from now) | |
US10028937 (Pediatric) | ABBVIE | Anti-viral compounds |
Dec, 2030
(6 years from now) | |
US10039754 (Pediatric) | ABBVIE | Anti-viral compounds |
Dec, 2030
(6 years from now) | |
US9586978 (Pediatric) | ABBVIE | Anti-viral compounds |
May, 2031
(7 years from now) | |
US8648037 (Pediatric) | ABBVIE | Macrocyclic proline derived HCV serine protease inhibitors |
Jul, 2032
(8 years from now) | |
US8937150 (Pediatric) | ABBVIE | Anti-viral compounds |
Nov, 2032
(8 years from now) | |
US10286029 | ABBVIE | Method for treating HCV |
Mar, 2034
(9 years from now) | |
US11484534 | ABBVIE | Methods for treating HCV |
Mar, 2034
(9 years from now) | |
US11484534 (Pediatric) | ABBVIE | Methods for treating HCV |
Sep, 2034
(10 years from now) | |
US10286029 (Pediatric) | ABBVIE | Method for treating HCV |
Sep, 2034
(10 years from now) | |
USRE48923 (Pediatric) | ABBVIE | Crystal forms |
Nov, 2035
(11 years from now) | |
US9321807 (Pediatric) | ABBVIE | Crystal forms |
Dec, 2035
(11 years from now) | |
US11246866 | ABBVIE | Solid pharmaceutical compositions for treating HCV |
Jun, 2036
(12 years from now) | |
US11246866 (Pediatric) | ABBVIE | Solid pharmaceutical compositions for treating HCV |
Dec, 2036
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-372) | Jun 10, 2028 |
Pediatric Exclusivity(PED) | Dec 10, 2028 |
New Chemical Entity Exclusivity(NCE) | Aug 03, 2022 |
New Dosing Schedule(D-175) | Sep 26, 2022 |
M(M-259) | Apr 10, 2023 |
Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient
NCE-1 date: 11 December, 2027
Market Authorisation Date: 10 June, 2021
Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg; Treatment of chronic hepatitis c virus (hcv) ge...
Dosage: PELLETS;ORAL; TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5061703 | ABBVIE | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Apr, 2015
(9 years ago) | |
US5061703 (Pediatric) | ABBVIE | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Oct, 2015
(8 years ago) |
Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 October, 2003
Treatment: Treatment of moderate to severe dementia of the alzheimer's type
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5061703 | ABBVIE | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Apr, 2015
(9 years ago) | |
US5061703 (Pediatric) | ABBVIE | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Oct, 2015
(8 years ago) | |
US8173708 | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
US8362085 | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
US8283379 | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(1 year, 6 months from now) | |
US8329752 | ABBVIE | Composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
US8598233 | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
US8168209 | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
US8283379 (Pediatric) | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
May, 2026
(2 years from now) | |
US8598233 (Pediatric) | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
US8168209 (Pediatric) | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
US8173708 (Pediatric) | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
US8329752 (Pediatric) | ABBVIE | Composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
US8362085 (Pediatric) | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
US8039009 | ABBVIE | Modified release formulations of memantine oral dosage forms |
Mar, 2029
(4 years from now) | |
US8039009 (Pediatric) | ABBVIE | Modified release formulations of memantine oral dosage forms |
Sep, 2029
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-138) | Jul 03, 2017 |
Pediatric Exclusivity(PED) | Jan 03, 2018 |
New Dosage Form(NDF) | Jun 21, 2013 |
Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 June, 2010
Treatment: Treatment of moderate to severe dementia of the alzheimer's type
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5061703 | ABBVIE | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Apr, 2015
(9 years ago) | |
US5061703 (Pediatric) | ABBVIE | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Oct, 2015
(8 years ago) | |
US8598233 | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
US8173708 | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
US8362085 | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
US8293794 | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(1 year, 6 months from now) | |
US8338485 | ABBVIE | Compositions for the treatment of CNS-related conditions |
Nov, 2025
(1 year, 6 months from now) | |
US8329752 | ABBVIE | Composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
US8338486 | ABBVIE | Methods for the treatment of CNS-related conditions |
Nov, 2025
(1 year, 6 months from now) | |
US8580858 | ABBVIE | Compositions for the treatment of CNS-related conditions |
Nov, 2025
(1 year, 6 months from now) | |
US8283379 | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(1 year, 6 months from now) | |
US8168209 | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
US8598233 (Pediatric) | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
US8283379 (Pediatric) | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
May, 2026
(2 years from now) | |
US8329752 (Pediatric) | ABBVIE | Composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
US8362085 (Pediatric) | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
US8173708 (Pediatric) | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
US8168209 (Pediatric) | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
US8039009 | ABBVIE | Modified release formulations of memantine oral dosage forms |
Mar, 2029
(4 years from now) | |
US8039009 (Pediatric) | ABBVIE | Modified release formulations of memantine oral dosage forms |
Sep, 2029
(5 years from now) | |
US8058291 | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
Dec, 2029
(5 years from now) |
Drugs and Companies using DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 July, 2016
Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6406715 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles |
Sep, 2013
(10 years ago) | |
US6746691 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
Sep, 2013
(10 years ago) | |
US6676967 | ABBVIE | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
Sep, 2013
(10 years ago) | |
US7011848 | ABBVIE | Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep, 2013
(10 years ago) | |
US6129930 | ABBVIE | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
Sep, 2013
(10 years ago) | |
US7998506 | ABBVIE | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep, 2013
(10 years ago) | |
US6818229 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
Feb, 2014
(10 years ago) | |
US6080428 | ABBVIE | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
May, 2017
(6 years ago) | |
US6469035 | ABBVIE | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
Mar, 2018
(6 years ago) |
Drugs and Companies using NIACIN ingredient
Market Authorisation Date: 28 July, 1997
Treatment: Intermediate rel nicotinic acid formulations having unique urinary metab profiles resulting from absorption profiles of nicotinic acid from the intermediate nicotinic acid formulations,suitable for tx...
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7011848 | ABBVIE | Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep, 2013
(10 years ago) | |
US6129930 | ABBVIE | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
Sep, 2013
(10 years ago) | |
US6406715 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles |
Sep, 2013
(10 years ago) | |
US6746691 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
Sep, 2013
(10 years ago) | |
US6080428 | ABBVIE | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
May, 2017
(6 years ago) |
Drugs and Companies using NIACIN ingredient
Market Authorisation Date: 28 July, 1997
Treatment: A method of using a nicotinic acid formulation to reduce elevated tc, ldl-c and tg levels, and raise hdl-c levels in patients with hyperlipidemia; Method of treating hyperlipidemia with nicotinic acid...
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5453510 | ABBVIE | Neuromuscular blocking agents |
Sep, 2012
(11 years ago) |
Drugs and Companies using CISATRACURIUM BESYLATE ingredient
Market Authorisation Date: 15 December, 1995
Treatment: Method of producing neuromuscular blockade
Dosage: INJECTABLE;INJECTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5453510 | ABBVIE | Neuromuscular blocking agents |
Sep, 2012
(11 years ago) |
Drugs and Companies using CISATRACURIUM BESYLATE ingredient
Market Authorisation Date: 15 December, 1995
Treatment: Method of producing neuromuscular blockade
Dosage: INJECTABLE;INJECTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5541206 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2013
(10 years ago) | |
US5635523 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2013
(10 years ago) | |
US5674882 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2013
(10 years ago) | |
US5948436 | ABBVIE | Pharmaceutical composition |
Sep, 2013
(10 years ago) | |
US5484801 | ABBVIE | Pharmaceutical composition for inhibiting HIV protease |
Jan, 2014
(10 years ago) | |
US5674882 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2014
(10 years ago) | |
US5541206 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2014
(10 years ago) | |
US5635523 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2014
(10 years ago) | |
US5948436 (Pediatric) | ABBVIE | Pharmaceutical composition |
Mar, 2014
(10 years ago) | |
US5648497 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2014
(9 years ago) | |
US5484801 (Pediatric) | ABBVIE | Pharmaceutical composition for inhibiting HIV protease |
Jul, 2014
(9 years ago) | |
US5648497 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2015
(9 years ago) | |
US6703403 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
US6037157 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
US6037157 (Pediatric) | ABBVIE | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
US6703403 (Pediatric) | ABBVIE | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
US6232333 | ABBVIE | Pharmaceutical composition |
Nov, 2017
(6 years ago) | |
US6232333 (Pediatric) | ABBVIE | Pharmaceutical composition |
May, 2018
(5 years ago) | |
US7148359 | ABBVIE | Polymorph of a pharmaceutical |
Jul, 2019
(4 years ago) | |
US7148359 (Pediatric) | ABBVIE | Polymorph of a pharmaceutical |
Jan, 2020
(4 years ago) | |
US7141593 | ABBVIE | Pharmaceutical formulations |
May, 2020
(3 years ago) | |
US7432294 | ABBVIE | Pharmaceutical formulations |
May, 2020
(3 years ago) | |
US7364752 | ABBVIE | Solid dispersion pharamaceutical formulations |
Nov, 2020
(3 years ago) | |
US7432294 (Pediatric) | ABBVIE | Pharmaceutical formulations |
Nov, 2020
(3 years ago) | |
US7141593 (Pediatric) | ABBVIE | Pharmaceutical formulations |
Nov, 2020
(3 years ago) | |
US7364752 (Pediatric) | ABBVIE | Solid dispersion pharamaceutical formulations |
May, 2021
(2 years ago) | |
US8691878 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
US8691878 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
US8399015 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
US8268349 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
US8470347 | ABBVIE | Self-emulsifying active substance formulation and use of this formulation |
Sep, 2026
(2 years from now) | |
US8470347 (Pediatric) | ABBVIE | Self-emulsifying active substance formulation and use of this formulation |
Mar, 2027
(2 years from now) |
Drugs and Companies using RITONAVIR ingredient
Market Authorisation Date: 29 June, 1999
Treatment: Use of norvir to inhibit hiv protease or to inhibit an hiv infection; Use of ritonavir in combination with any reverse transcriptase inhibitor; Treatment of hiv-infection in combination with other ant...
Dosage: CAPSULE;ORAL; TABLET;ORAL; SOLUTION;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7462625 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jan, 2021
(3 years ago) | |
US6872728 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jan, 2021
(3 years ago) | |
US7056927 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Sep, 2024
(4 months from now) | |
US7419983 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods related thereto |
Jul, 2029
(5 years from now) | |
US11542239 | ABBVIE | Elagolix sodium compositions and processes |
Jul, 2039
(15 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7179815 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Mar, 2021
(3 years ago) | |
US11459305 | ABBVIE | Processes for the preparation of uracil derivatives |
Nov, 2028
(4 years from now) | |
US10881659 | ABBVIE | Methods of treating heavy menstrual bleeding |
Mar, 2034
(9 years from now) | |
US11045470 | ABBVIE | Methods of treating heavy menstrual bleeding |
Mar, 2034
(9 years from now) | |
US11690845 | ABBVIE | Methods of administering elagolix |
Aug, 2040
(16 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 23, 2023 |
New Product(NP) | May 29, 2023 |
NCE-1 date: 23 July, 2022
Market Authorisation Date: 29 May, 2020
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids); Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) using 300 mg elagolix while c...
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6872728 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jan, 2021
(3 years ago) | |
US7462625 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jan, 2021
(3 years ago) | |
US7056927 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Sep, 2024
(4 months from now) | |
US7419983 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods related thereto |
Jul, 2029
(5 years from now) | |
US11542239 | ABBVIE | Elagolix sodium compositions and processes |
Jul, 2039
(15 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7179815 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Mar, 2021
(3 years ago) | |
US7176211 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jul, 2024
(2 months from now) | |
US11344551 | ABBVIE | Methods of treating heavy menstrual bleeding |
Mar, 2034
(9 years from now) | |
US11707464 | ABBVIE | Methods of treating heavy menstrual bleeding |
Mar, 2034
(9 years from now) | |
US10537572 | ABBVIE | Methods of administering elagolix |
Sep, 2036
(12 years from now) | |
US10682351 | ABBVIE | Methods of administering elagolix |
Sep, 2036
(12 years from now) | |
US11690854 | ABBVIE | Methods of treating heavy menstrual bleeding |
Apr, 2038
(13 years from now) | |
US11690845 | ABBVIE | Methods of administering elagolix |
Aug, 2040
(16 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 23, 2023 |
Drugs and Companies using ELAGOLIX SODIUM ingredient
NCE-1 date: 23 July, 2022
Market Authorisation Date: 23 July, 2018
Treatment: Management of moderate to severe pain associated with endometriosis; Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women havi...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5601839 | ABBVIE | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr, 2015
(9 years ago) | |
US5834010 | ABBVIE | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr, 2015
(9 years ago) | |
US7081251 | ABBVIE | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) | |
US7081250 | ABBVIE | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) | |
US7081249 | ABBVIE | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) | |
US7179483 | ABBVIE | Compositions and methods for transdermal oxybutynin therapy |
Apr, 2020
(4 years ago) | |
US6743441 | ABBVIE | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) | |
US7081252 | ABBVIE | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jan 25, 2016 |
Drugs and Companies using OXYBUTYNIN ingredient
Market Authorisation Date: 25 January, 2013
Treatment: Treatment of patients with an overactive bladder
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8063031 | ABBVIE | Implants and methods for treating inflammation-mediated conditions of the eye |
Oct, 2020
(3 years ago) | |
US9775849 | ABBVIE | Implants and methods for treating inflammation-mediated conditions of the eye |
Oct, 2020
(3 years ago) | |
US9283178 | ABBVIE | Methods for treating edema in the eye and intraocular implants for use therefor |
Oct, 2020
(3 years ago) | |
US9592242 | ABBVIE | Methods for treating edema in the eye and intraocular implants for use therefor |
Oct, 2020
(3 years ago) | |
US8043628 | ABBVIE | Methods for reducing edema |
Oct, 2020
(3 years ago) | |
US6726918 | ABBVIE | Methods for treating inflammation-mediated conditions of the eye |
Oct, 2020
(3 years ago) | |
US8088407 | ABBVIE | Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
Oct, 2020
(3 years ago) | |
US7033605 | ABBVIE | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
Oct, 2020
(3 years ago) | |
US9012437 | ABBVIE | Implants and methods for treating inflammation-mediated conditions of the eye |
Oct, 2020
(3 years ago) | |
US7767223 | ABBVIE | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use |
Nov, 2021
(2 years ago) | |
US8506987 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
US9192511 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
US10076526 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
US8034370 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
US8034366 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
US10702539 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
US6899717 | ABBVIE | Methods and apparatus for delivery of ocular implants |
Nov, 2023
(6 months ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | Jun 17, 2012 |
New Indication(I-686) | Jun 29, 2017 |
Orphan Drug Exclusivity(ODE) | Sep 24, 2017 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 17 June, 2009
Treatment: Intravitreal treatment of diabetic macular edema; Treatment of macular edema; Treatment of uveitis; Treatment of non-infectious uveitis affecting the posterior segment of the eye; Delivering an ocular...
Dosage: IMPLANT;INTRAVITREAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9499545 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(7 years from now) | |
US8754096 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(8 years from now) | |
US9850246 | ABBVIE | Process for making CGRP receptor antagonists |
Mar, 2033
(8 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10117836 | ABBVIE | Tablet formulation for CGRP active compounds |
Jan, 2035
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-909) | Apr 17, 2026 |
New Chemical Entity Exclusivity(NCE) | Sep 28, 2026 |
Drugs and Companies using ATOGEPANT ingredient
NCE-1 date: 28 September, 2025
Market Authorisation Date: 28 September, 2021
Treatment: Preventive treatment of migraine in adults
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7189761 | ABBVIE | Nitric oxide donor composition and method for treatment of anal disorders |
May, 2014
(9 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jun 21, 2014 |
Drugs and Companies using NITROGLYCERIN ingredient
Market Authorisation Date: 21 June, 2011
Treatment: Rectiv is a nitrate vasodilator indicated for the treatment of moderate to severe pain associated with chronic anal fissure
Dosage: OINTMENT;INTRA-ANAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5474979 | ABBVIE | Nonirritating emulsions for sensitive tissue |
May, 2014
(9 years ago) | |
US8642556 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) | |
US9248191 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) | |
US8685930 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) | |
US8629111 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) | |
US8633162 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) | |
US8648048 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 December, 2002
Treatment: Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).; Increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Dosage: EMULSION;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8629111 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) | |
US8642556 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) | |
US8633162 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) | |
US9248191 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) | |
US8685930 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) | |
US8648048 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) | |
US8292129 | ABBVIE | Dispensing device |
Feb, 2031
(6 years from now) | |
US8561859 | ABBVIE | Dispensing device |
Apr, 2032
(7 years from now) | |
US9676525 | ABBVIE | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids |
Feb, 2034
(9 years from now) | |
US9669974 | ABBVIE | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids |
May, 2034
(10 years from now) |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 December, 2002
Treatment: Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).; Increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Dosage: EMULSION;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
USRE47221 | ABBVIE | Tricyclic compounds |
Dec, 2030
(6 years from now) | |
US8962629 | ABBVIE | Tricyclic compounds |
Jan, 2031
(6 years from now) | |
US10981923 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US11186584 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US11773105 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US11680069 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US11661425 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US9951080 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US11718627 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11524964 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US10344036 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US10995095 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US11773106 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US11795175 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US11535624 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US11535625 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US11535626 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1 carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US11365198 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US10981924 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US10730883 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US9963459 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US11780847 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US11787815 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US11780848 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US11767326 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US10550126 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US10519164 | ABBVIE | Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US11198697 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US10597400 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US10202393 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US11512092 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
US11564922 | ABBVIE | Methods of treating crohn's disease and ulcerative colitis |
Mar, 2038
(13 years from now) | |
US11607411 | ABBVIE | Methods of treating Crohn's disease and ulcerative colitis |
Mar, 2038
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
New Indication(I-919) | May 18, 2026 |
New Indication(I-886) | Mar 16, 2025 |
New Indication(I-888) | Apr 29, 2025 |
New Indication(I-880) | Dec 14, 2024 |
New Indication(I-883) | Jan 14, 2025 |
Drugs and Companies using UPADACITINIB ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: Treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults and pediatric patients 12 years of age and ol...
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6992110 | ABBVIE | Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain |
Nov, 2021
(2 years ago) | |
US7888342 | ABBVIE | Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain |
Nov, 2021
(2 years ago) | |
US6602911 | ABBVIE | Methods of treating fibromyalgia |
Jan, 2023
(1 year, 3 months ago) | |
US7994220 | ABBVIE | Milnacipran for the long-term treatment of fibromyalgia syndrome |
Sep, 2029
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 14, 2014 |
Drugs and Companies using MILNACIPRAN HYDROCHLORIDE ingredient
NCE-1 date: 14 January, 2013
Market Authorisation Date: 14 January, 2009
Treatment: Management of fibromyalgia (fm); Management of fibromyalgia
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6129930 | ABBVIE | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
Sep, 2013
(10 years ago) | |
US6406715 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles |
Sep, 2013
(10 years ago) | |
US6818229 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
Sep, 2013
(10 years ago) | |
US7998506 | ABBVIE | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep, 2013
(10 years ago) | |
US6746691 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
Sep, 2013
(10 years ago) | |
US6676967 | ABBVIE | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
Sep, 2013
(10 years ago) | |
US7011848 | ABBVIE | Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep, 2013
(10 years ago) | |
US6080428 | ABBVIE | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
May, 2017
(6 years ago) | |
US6469035 | ABBVIE | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
Mar, 2018
(6 years ago) |
Drugs and Companies using NIACIN; SIMVASTATIN ingredient
Market Authorisation Date: 15 February, 2008
Treatment: Adjunct to diet to reduce elevated total-c, ldl-c, non-hdl-c, apo b, tg, and lp(a) levels and to increase hdl-c in patients with primary hypercholesterolemia, mixed dyslipidemia, and hypertriglyceride...
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5721244 | ABBVIE | Combination of angiotensin-converting enzyme inhibitors with calcium antagonists as well as their use in drugs |
Feb, 2015
(9 years ago) |
Drugs and Companies using TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE ingredient
Market Authorisation Date: 22 October, 1996
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8642538 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(5 years from now) | |
US8420596 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(6 years from now) | |
US8691938 | ABBVIE | Anti-viral compounds |
Apr, 2032
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6703403 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
US6037157 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
US6037157 (Pediatric) | ABBVIE | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
US6703403 (Pediatric) | ABBVIE | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
US7148359 | ABBVIE | Polymorph of a pharmaceutical |
Jul, 2019
(4 years ago) | |
US7148359 (Pediatric) | ABBVIE | Polymorph of a pharmaceutical |
Jan, 2020
(4 years ago) | |
US7364752 | ABBVIE | Solid dispersion pharamaceutical formulations |
Nov, 2020
(3 years ago) | |
US7364752 (Pediatric) | ABBVIE | Solid dispersion pharamaceutical formulations |
May, 2021
(2 years ago) | |
US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
US8268349 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
US8399015 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
US9006387 | ABBVIE | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
US9044480 | ABBVIE | Compositions and methods for treating HCV |
Apr, 2031
(6 years from now) | |
US8686026 | ABBVIE | Solid compositions |
Jun, 2031
(7 years from now) | |
US8420596 (Pediatric) | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Oct, 2031
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jul 24, 2018 |
New Indication(I-743) | Jul 24, 2018 |
New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 24 July, 2015
Treatment: Use of ritonavir as a potent cyp3a inhibitor to increase plasma drug concentration of paritaprevir and overall drug exposure for treatment of hcv infection; Treatment of hcv infection using ombitasvir...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6417175 | ABBVIE | Phosphonocephem derivatives, process for the preparation of the same, and use thereof |
Dec, 2018
(5 years ago) | |
US6906055 | ABBVIE | Phosphonocephem compound |
Dec, 2021
(2 years ago) | |
US7419973 | ABBVIE | Phosphonocephem compound |
Dec, 2021
(2 years ago) | |
US9629861 | ABBVIE | Compositions and methods for treating bacterial infections using ceftaroline |
Sep, 2030
(6 years from now) | |
US8247400 | ABBVIE | Cephem compounds useful for the treatment of bacterial infections |
Feb, 2031
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Sep 13, 2022 |
New Chemical Entity Exclusivity(NCE) | Oct 29, 2015 |
Drugs and Companies using CEFTAROLINE FOSAMIL ingredient
NCE-1 date: 29 October, 2014
Market Authorisation Date: 29 October, 2010
Treatment: Method of treating bacterial infections
Dosage: POWDER;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5656650 | ABBVIE | Angiotensin II receptor blocking compositions |
Aug, 2014
(9 years ago) |
Drugs and Companies using EPROSARTAN MESYLATE ingredient
Market Authorisation Date: 22 December, 1997
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5656650 | ABBVIE | Angiotensin II receptor blocking compositions |
Aug, 2014
(9 years ago) |
Drugs and Companies using EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE ingredient
Market Authorisation Date: 01 November, 2001
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6277405 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
Jan, 2018
(6 years ago) | |
US7037529 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
Jan, 2018
(6 years ago) | |
US6589552 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
Jan, 2018
(6 years ago) | |
US6652881 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability |
Jan, 2018
(6 years ago) | |
US7041319 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailabilty |
Jan, 2018
(6 years ago) | |
US6074670 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
Jan, 2018
(6 years ago) | |
US6375986 | ABBVIE | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
Sep, 2020
(3 years ago) | |
US7276249 | ABBVIE | Nanoparticulate fibrate formulations |
Feb, 2023
(1 year, 2 months ago) | |
US7320802 | ABBVIE | Methods of treatment using nanoparticulate fenofibrate compositions |
Feb, 2023
(1 year, 2 months ago) |
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 05 November, 2004
Treatment: Adjunctive therapy to diet in adults to reduce ldl-c, total-c, triglycerides and apo b, and increase hdl-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types iia, iib) and to t...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7259186 | ABBVIE | Salts of fenofibric acid and pharmaceutical formulations thereof |
Jan, 2025
(8 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Dec 15, 2011 |
Drugs and Companies using CHOLINE FENOFIBRATE ingredient
Market Authorisation Date: 15 December, 2008
Treatment: NA
Dosage: CAPSULE, DELAYED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9499545 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(7 years from now) | |
US8754096 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(8 years from now) | |
US8912210 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Dec, 2033
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9833448 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(7 years from now) | |
US10117836 | ABBVIE | Tablet formulation for CGRP active compounds |
Jan, 2035
(10 years from now) | |
US11857542 | ABBVIE | Treatment of migraine |
Dec, 2041
(17 years from now) | |
US11717515 | ABBVIE | Treatment of migraine |
Dec, 2041
(17 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 23, 2024 |
Drugs and Companies using UBROGEPANT ingredient
NCE-1 date: 24 December, 2023
Market Authorisation Date: 23 December, 2019
Treatment: Acute treatment of migraine with or without aura in adults; Acute treatment of migraine with or without aura in a patient with severe renal impairment; Acute treatment of migraine with or without aura...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5990176 | ABBVIE | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
Jan, 2017
(7 years ago) | |
US6288127 | ABBVIE | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
Jan, 2017
(7 years ago) | |
US6444859 | ABBVIE | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
Jan, 2017
(7 years ago) | |
US6288127 (Pediatric) | ABBVIE | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
Jul, 2017
(6 years ago) | |
US6444859 (Pediatric) | ABBVIE | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
Jul, 2017
(6 years ago) | |
US5990176 (Pediatric) | ABBVIE | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
Jul, 2017
(6 years ago) | |
US6074668 | ABBVIE | Container for an inhalation anesthetic |
Jan, 2018
(6 years ago) | |
US6074668 (Pediatric) | ABBVIE | Container for an inhalation anesthetic |
Jul, 2018
(5 years ago) |
Drugs and Companies using SEVOFLURANE ingredient
Market Authorisation Date: 07 June, 1995
Treatment: NA
Dosage: LIQUID;INHALATION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8546399 | ABBVIE | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
Jun, 2031
(7 years from now) | |
US10730873 | ABBVIE | Salts and crystalline forms of an apoptosis-inducing agent |
Nov, 2031
(7 years from now) | |
US8722657 | ABBVIE | Salts and crystalline forms of an apoptosis-inducing agent |
Jan, 2032
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9174982 | ABBVIE | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
May, 2030
(6 years from now) | |
US11369599 | ABBVIE | Melt-extruded solid dispersions containing an apoptosis-inducing agent |
May, 2032
(8 years from now) | |
US11590128 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(9 years from now) | |
US11413282 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(9 years from now) | |
US10993942 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(9 years from now) | |
US9539251 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(9 years from now) | |
US11110087 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-185) | Jun 08, 2025 |
Orphan Drug Exclusivity(ODE-211) | Nov 21, 2025 |
Orphan Drug Exclusivity(ODE-239) | May 15, 2026 |
New Chemical Entity Exclusivity(NCE) | Apr 11, 2021 |
Orphan Drug Exclusivity(ODE) | Apr 11, 2023 |
New Indication(I-789) | Nov 21, 2021 |
New Indication(I-795) | May 15, 2022 |
M(M-265) | Oct 16, 2023 |
Orphan Drug Exclusivity(ODE-114) | Apr 11, 2023 |
M(M-228) | Jun 08, 2021 |
New Indication(I-782) | Jun 08, 2021 |
Drugs and Companies using VENETOCLAX ingredient
NCE-1 date: 11 April, 2020
Market Authorisation Date: 11 April, 2016
Treatment: Treatment in combination with azacitidine or decitabine or low-dose cytarabine of newly-diagnosed acute myeloid leukemia (aml) in adults who are age 75 years or older, or who have comorbidities that p...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10213415 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
US8609709 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
US7786158 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
US8691860 | ABBVIE | Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(4 years from now) | |
US9115091 | ABBVIE | Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(4 years from now) | |
US7741356 | ABBVIE | Compounds as opioid receptor modulators |
May, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8772325 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
US9700542 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
US9205076 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
US8344011 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
US9789125 | ABBVIE | Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(4 years from now) | |
US9364489 | ABBVIE | Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(4 years from now) | |
US10188632 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
US11229627 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
US9675587 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
US11484527 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
US11007179 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
US11311516 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
US11160792 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
US11090291 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 27, 2020 |
Drugs and Companies using ELUXADOLINE ingredient
NCE-1 date: 28 May, 2019
Market Authorisation Date: 27 May, 2015
Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline).; Reduction of the frequency of abdominal pain and diarrhea, in an inflammatory bowel disease with diarrhea (ibs-...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6348216 | ABBVIE | Ibuprofen and narcotic analgesic compositions |
Jun, 2017
(6 years ago) | |
US6599531 | ABBVIE | Method of making ibuprofen and narcotic analgesic compositions |
Jun, 2017
(6 years ago) |
Drugs and Companies using HYDROCODONE BITARTRATE; IBUPROFEN ingredient
Market Authorisation Date: 23 September, 1997
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8501238 | ABBVIE | Anti-infective agents and uses thereof |
Dec, 2028
(4 years from now) | |
US8188104 | ABBVIE | Anti-infective agents and uses thereof |
May, 2029
(5 years from now) | |
US8642538 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(5 years from now) | |
US8420596 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(6 years from now) | |
US8691938 | ABBVIE | Anti-viral compounds |
Apr, 2032
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6037157 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
US6703403 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
US7148359 | ABBVIE | Polymorph of a pharmaceutical |
Jul, 2019
(4 years ago) | |
US7364752 | ABBVIE | Solid dispersion pharamaceutical formulations |
Nov, 2020
(3 years ago) | |
US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
US9139536 | ABBVIE | Anti-infective agents and uses thereof |
Nov, 2028
(4 years from now) | |
US9006387 | ABBVIE | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
US9044480 | ABBVIE | Compositions and methods for treating HCV |
Apr, 2031
(6 years from now) | |
US8686026 | ABBVIE | Solid compositions |
Jun, 2031
(7 years from now) | |
US8492386 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
US8466159 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
US8680106 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
US8685984 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
US9629841 | ABBVIE | Formulations of pyrimidinedione derivative compounds |
Oct, 2033
(9 years from now) | |
US10201542 | ABBVIE | Formulations of pyrimidinedione derivative compounds |
Oct, 2033
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
New Dosing Schedule(D-163) | Apr 22, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Treatment: Use of ritonavir as a potent cyp3a inhibitor to increase plasma drug concentration of paritaprevir and overall drug exposure for treatment of hcv infection; Treatment of hcv infection using dasabuvir;...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8501238 | ABBVIE | Anti-infective agents and uses thereof |
Sep, 2028
(4 years from now) | |
US8188104 | ABBVIE | Anti-infective agents and uses thereof |
May, 2029
(5 years from now) | |
US8642538 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(5 years from now) | |
US8420596 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(6 years from now) | |
US8691938 | ABBVIE | Anti-viral compounds |
Apr, 2032
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7148359 | ABBVIE | Polymorph of a pharmaceutical |
Jul, 2019
(4 years ago) | |
US7364752 | ABBVIE | Solid dispersion pharamaceutical formulations |
Nov, 2020
(3 years ago) | |
US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
US9139536 | ABBVIE | Anti-infective agents and uses thereof |
Nov, 2028
(4 years from now) | |
US9006387 | ABBVIE | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
US9044480 | ABBVIE | Compositions and methods for treating HCV |
Apr, 2031
(6 years from now) | |
US8686026 | ABBVIE | Solid compositions |
Jun, 2031
(7 years from now) | |
US10201584 | ABBVIE | Compositions and methods for treating HCV |
May, 2032
(8 years from now) | |
US10201541 | ABBVIE | Compositions and methods for treating HCV |
May, 2032
(8 years from now) | |
US8492386 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
US8685984 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
US8466159 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
US8680106 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
US9744170 | ABBVIE | Solid antiviral dosage forms |
Jan, 2035
(10 years from now) | |
US10105365 | ABBVIE | Solid antiviral dosage forms |
Jan, 2035
(10 years from now) | |
US9333204 | ABBVIE | Solid antiviral dosage forms |
Jan, 2035
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 22 July, 2016
Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using dasabuvir/ombitasvir/paritaprev...
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8673921 | ABBVIE | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(1 year, 10 months ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5532241 | ABBVIE | Piperidines and piperazines |
Sep, 2014
(9 years ago) | |
US8236804 | ABBVIE | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Jun, 2022
(1 year, 10 months ago) | |
US7834020 | ABBVIE | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(1 year, 10 months ago) | |
US8193195 | ABBVIE | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(1 year, 10 months ago) | |
US8193195 (Pediatric) | ABBVIE | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(1 year, 4 months ago) | |
US8236804 (Pediatric) | ABBVIE | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Dec, 2022
(1 year, 4 months ago) | |
US8673921 (Pediatric) | ABBVIE | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(1 year, 4 months ago) | |
US7834020 (Pediatric) | ABBVIE | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(1 year, 4 months ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-146) | Mar 16, 2018 |
M(M-254) | Jan 31, 2023 |
Pediatric Exclusivity(PED) | Jul 31, 2023 |
New Chemical Entity Exclusivity(NCE) | Jan 21, 2016 |
Drugs and Companies using VILAZODONE HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2022
Market Authorisation Date: 21 January, 2011
Treatment: Treatment of major depressive disorder (mdd)
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7943621 | ABBVIE | Salts of piperazine compounds as D3/D2 antagonists |
Dec, 2028
(4 years from now) | |
US7737142 | ABBVIE | (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists |
Sep, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE47350 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(5 years from now) | |
USRE49110 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(5 years from now) | |
USRE49302 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-904) | Dec 16, 2025 |
M(M-213) | Nov 09, 2020 |
New Indication(I-798) | May 24, 2022 |
New Chemical Entity Exclusivity(NCE) | Sep 17, 2020 |
Drugs and Companies using CARIPRAZINE HYDROCHLORIDE ingredient
NCE-1 date: 18 September, 2019
Market Authorisation Date: 17 September, 2015
Treatment: Treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine; Treatment of schizophrenia with cariprazine; Adjunctive therapy to antidepressants for the tr...
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10610518 | ABBVIE | Presbyopia treatments |
Apr, 2039
(14 years from now) | |
US11285134 | ABBVIE | Presbyopia treatments |
Apr, 2039
(14 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-187) | Mar 28, 2026 |
New Product(NP) | Oct 28, 2024 |
Drugs and Companies using PILOCARPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 October, 2021
Treatment: Use of vuity for the treatment of presbyopia in adults
Dosage: SOLUTION;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5246925 (Pediatric) | ABBVIE | 19-nor-vitamin D compounds for use in treating hyperparathyroidism |
Oct, 2012
(11 years ago) | |
US5587497 | ABBVIE | 19-nor-vitamin D compounds |
Dec, 2013
(10 years ago) | |
US5587497 (Pediatric) | ABBVIE | 19-nor-vitamin D compounds |
Jun, 2014
(9 years ago) | |
US5597815 | ABBVIE | Prevention of hyperphosphatemia in kidney disorder patients |
Jul, 2015
(8 years ago) | |
US5597815 (Pediatric) | ABBVIE | Prevention of hyperphosphatemia in kidney disorder patients |
Jan, 2016
(8 years ago) | |
US6136799 | ABBVIE | Cosolvent formulations |
Apr, 2018
(6 years ago) | |
US6361758 | ABBVIE | Cosolvent formulations |
Apr, 2018
(6 years ago) | |
US6136799 (Pediatric) | ABBVIE | Cosolvent formulations |
Oct, 2018
(5 years ago) | |
US6361758 (Pediatric) | ABBVIE | Cosolvent formulations |
Oct, 2018
(5 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Oct 18, 2019 |
Orphan Drug Exclusivity(ODE) | Oct 18, 2023 |
New Indication(I-599) | Jun 29, 2012 |
Orphan Drug Exclusivity(ODE-125) | Oct 18, 2023 |
Drugs and Companies using PARICALCITOL ingredient
Market Authorisation Date: 26 May, 2005
Treatment: Prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (ckd) stage 5, which may result in renal osteodystrophy, while avoiding hyperphosphatemia
Dosage: CAPSULE;ORAL; SOLUTION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5880283 | ABBVIE | 8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same |
Dec, 2015
(8 years ago) | |
US5880283 (Pediatric) | ABBVIE | 8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same |
Jun, 2016
(7 years ago) | |
US6333045 | ABBVIE | Aqueous liquid pharmaceutical composition comprised of gatifloxacin |
Aug, 2019
(4 years ago) | |
US6333045 (Pediatric) | ABBVIE | Aqueous liquid pharmaceutical composition comprised of gatifloxacin |
Feb, 2020
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | May 18, 2013 |
Drugs and Companies using GATIFLOXACIN ingredient
Market Authorisation Date: 18 May, 2010
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC